Rigor Reviewed

Rigor-Reviewed Manuscript

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Name: Αlpha¹ Rigor Record — Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
Item: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial
Rating: 59
Author: Αlpha¹

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 6 high issues for “Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were found (48) but none could be checked — every lookup failed or lacked a DOI.
Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-designed phase 1 trial with a strong scientific premise, transparent reporting, and adequate ethical and resource documentation. However, several methodological and reporting gaps temper the robustness: the randomization method and blinding details are underdescribed, formal power analysis is absent, confidence intervals for main efficacy outcomes are not reported, analysis code is not shared, and the specific IRB is not named. These are common issues in early-phase clinical trial reporting but are flagged here for completeness.

The evaluation is based on the full text of the published paper, with three independent reviews from the same model and a copyedit pass. The statistics verification component checked no tests (coverage note: only tests with test statistic+df or effect+CI are verifiable; none such were present). The citation check found no retracted or unfound references. The preregistration is confirmed. The integrity concerns are low-severity. The paper is a published clinical trial; the assessment is a post-publication robustness audit.

10 major claims checked against the paper's own evidence: all adequately supported.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction reviews the ANGPTL family, ANGPTL3/8 complex biology, and prior ANGPTL3 inhibitors (evinacumab, vupanorsen, zodasiran), highlighting the limitations and the rationale for targeting ANGPTL3/8 specifically. The hypothesis (that LY3475766 will safely reduce atherogenic lipoproteins) follows logically from the cited evidence. The discussion acknowledges limitations of prior work (e.g., HDL-C lowering with ANGPTL3 inhibitors) and positions the current study as addressing those gaps.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific foundation linking the ANGPTL3/8 complex to LPL inhibition and dyslipidemia, and justifies the target and the antibody.

Evidence

direct quote[Introduction, paragraphs 1-5]

“Recent studies on how the ANGPTL protein family modulates LPL activity have identified the mechanisms by which LPL activity is controlled in a tissue-specific manner”